Pathogenesis and Glycemic Management of Type 2 Diabetes Mellitus: A Physiological Approach

被引:2
作者
Ismail-Beigi, Faramarz [1 ,2 ]
机构
[1] Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44106 USA
关键词
beta-cell number; disposition index; glycemic target range; insulin resistance; LIFE-STYLE INTERVENTIONS; NONCOMMUNICABLE DISEASES; SUSCEPTIBILITY LOCI; INSULIN-SECRETION; NATURAL-HISTORY; GLUCOSE CONTROL; FOLLOW-UP; ASSOCIATION; THERAPY; SAFETY;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Type 2 diabetes (T2DM) is an incompletely understood chronic, progressive multifactorial disease with insulin resistance and decreased beta-cell function playing dominant roles in its genesis. The worldwide incidence of the disease is rapidly increasing to pandemic proportions. The increase in incidence of T2DM is attributable to changes in lifestyle, diet and obesity, but other causes remain to be defined. The disease is a major cause of early mortality due to atherosclerosis and cardiovascular disease (CVD), and is the leading cause of blindness, leg amputations, and chronic renal disease. Hyperglycemia inT2DM becomes manifest once insulin secretion is no longer adequate for the metabolic demands of the individual. The approach to glycemic management of the disease is increasingly based on understanding the underlying pathophysiology. Efforts to maintain and preserve beta-cell function during the earlier phases of the disease may have important implications in prevention of subsequent complications of TDM. Finally, the approach to glycemic management of the disease should be individualized by considering the psycho-socio-economic condition of each patient, and glycemic targets should reflect presence of comorbid conditions, age of the patient, the stage of their disease in terms of duration, presence of macro- and micro-vascular complications, and propensity for severe hypoglycemia.
引用
收藏
页码:239 / 246
页数:8
相关论文
共 71 条
[1]  
Amer Coll Endocrinologists Board T, 2010, ENDOCR PRACT, V16, P155
[2]   Efficacy and safety of incretin therapy in type 2 diabetes - Systematic review and meta-analysis [J].
Amori, Renee E. ;
Lau, Joseph ;
Pittas, Anastassios G. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 298 (02) :194-206
[3]  
[Anonymous], NEW ENGL J MED
[4]  
[Anonymous], AM J MED
[5]  
[Anonymous], BIOCH PHARM
[6]   Response to comment on: American Diabetes Association. Standards of medical care in diabetes-2011 (vol 34, pg e54, 2011) [J].
Wysham, C. H. ;
Kirkman, M. S. .
DIABETES CARE, 2011, 34 (08) :1887-1887
[7]   UN High-Level Meeting on Non-Communicable Diseases: addressing four questions [J].
Beaglehole, Robert ;
Bonita, Ruth ;
Alleyne, George ;
Horton, Richard ;
Li, Liming ;
Lincoln, Paul ;
Mbanya, Jean Claude ;
McKee, Martin ;
Moodie, Rob ;
Nishtar, Sania ;
Piot, Peter ;
Reddy, K. Srinath ;
Stuckler, David .
LANCET, 2011, 378 (9789) :449-455
[8]   Comparative Effectiveness and Safety of Medications for Type 2 Diabetes: An Update Including New Drugs and 2-Drug Combinations [J].
Bennett, Wendy L. ;
Maruthur, Nisa M. ;
Singh, Sonal ;
Segal, Jodi B. ;
Wilson, Lisa M. ;
Chatterjee, Ranee ;
Marinopoulos, Spyridon S. ;
Puhan, Milo A. ;
Ranasinghe, Padmini ;
Block, Lauren ;
Nicholson, Wanda K. ;
Hutfless, Susan ;
Bass, Eric B. ;
Bolen, Shari .
ANNALS OF INTERNAL MEDICINE, 2011, 154 (09) :602-613
[9]   Gluconeogenesis in moderately and severely hyperglycemic patients with type 2 diabetes mellitus [J].
Boden, G ;
Chen, XH ;
Stein, TP .
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM, 2001, 280 (01) :E23-E30
[10]   Systematic review: Comparative effectiveness and safety of oral medications for type 2 diabetes Mellitus [J].
Bolen, Shari ;
Feldman, Leonard ;
Vassy, Jason ;
Wilson, Lisa ;
Yeh, Hsin-Chieh ;
Marinopoulos, Spyriclon ;
Wiley, Crystal ;
Selvin, Elizabeth ;
Wilson, Renee ;
Bass, Eric B. ;
Brancati, Frederick L. .
ANNALS OF INTERNAL MEDICINE, 2007, 147 (06) :386-399